MNPR · XBRL financial data

Monopar Therapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (MNPR's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	—	—	—	—	0	0
Research and development	4,065	6,493	7,592	5,600	13,006	9,904
General and administrative	2,444	2,634	2,945	3,231	3,156	6,800
Total operating expenses	6,509	9,127	10,537	8,831	16,162	16,704
Operating income (loss)	(6,509)	(9,127)	(10,537)	(8,831)	(16,162)	(16,704)
Interest income	—	—	—	429	404	2,988
Income tax expense (benefit)	18	0	0	1	1	1
Net income (loss)	(6,305)	(9,103)	(10,516)	(8,402)	(15,586)	(13,717)
Earnings per share, basic USD per share	—	—	(0.83)	(0.61)	(4.11)	(1.85)
Weighted average shares, basic thousands of shares	—	12,471	12,718	13,824	3,790	7,411

Fiscal years (MNPR's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	16,737	20,304	8,186	7,266	45,816	61,834
Marketable securities	—	—	12,182	6,545	45,532	60,876
Total current assets	16,800	20,522	13,166	7,333	60,291	140,463
Right-of-use asset	—	0	61	13	0	255
Total assets	16,869	20,522	13,227	7,345	60,291	140,718
Total current liabilities	1,177	1,581	3,129	1,757	5,254	2,735
Lease liability, non-current	—	0	8	0	0	155
Total liabilities	1,177	1,581	3,137	1,757	5,254	2,890
Accumulated deficit	(32,185)	(41,288)	(51,804)	(60,206)	(75,793)	(89,510)
Total stockholders' equity	15,692	18,941	10,090	5,588	55,037	137,828
Total liabilities and equity	16,869	20,522	13,227	7,345	60,291	140,718
Common shares outstanding (cover page) thousands of shares	12,567	12,605	13,193	17,455	6,113	6,692

Fiscal years (MNPR's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(6,305)	(9,103)	(10,516)	(8,402)	(15,586)	(13,717)
Stock-based compensation	—	—	1,641	1,898	1,141	4,838
Net cash from operating activities	(4,662)	7,317	(7,229)	(7,858)	(6,404)	(12,201)
Net cash from investing activities	—	0	(4,919)	4,928	(14,338)	(63,453)
Proceeds from issuing common stock	8,175	—	109	2,074	4,202	0
Share repurchases	—	—	—	—	0	35,000
Net cash from financing activities	8,182	10,880	33	2,027	59,292	91,574
Net change in cash	—	3,567	(12,118)	(920)	38,550	16,017

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Monopar Therapeutics	52,758	0*	(3,247)*	6.7M	32.4 quarters	Q2 FY26 10-QJun 30, 2026
Forte Biosciences	49,629	not reported	(22,702)*	21.2M	8.7 quarters	Q2 FY26 10-QJun 30, 2026
Sangamo Therapeutics	27,586	1,442	(19,282)	414.3M	1.4 quarters	Q1 FY26 10-QMar 31, 2026
Lineage Cell Therapeutics	37,355	1,069	(7,244)*	252.9M	7.0 quarters	Q2 FY26 10-QJun 30, 2026
Alpha Cognition	41,384	6,093	(6,859)*	21.8M	6.0 quarters	Q2 FY26 10-QJun 30, 2026
Aclaris Therapeutics	19,167	1,629	(19,847)*	147.2M	4.6 quarters	Q2 FY26 10-QJun 30, 2026
Neurogene	112,485	not reported	(23,761)*	20.0M	9.5 quarters	Q2 FY26 10-QJun 30, 2026
4D Molecular Therapeutics	70,372	3,781	(69,999)*	55.2M	5.2 quarters	Q2 FY26 10-QJun 30, 2026
Puma Biotechnology	36,537	56,502	1,624*	51.6M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.